Moving Life Science Innovations along the path
From Discovery To Development To Delivery
OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.
OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.
Arizona’s bioscience industry is growing rapidly with over 34,000 jobs spanning over 2,000 business establishments in 2020. The industry’s job base grew 5.4% in Arizona from 2018-2020, more than tripling the U.S. growth rate of 1.4%. Arizona’s universities conducted nearly $623 million in R&D activities in bioscience-related fields in 2020, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased again in 2021, and during the 2018-2021 period totaled $532 million.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.
AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.
AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.
Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.
Success Stories – Good News from Arizona’s BioIndustry
BIO Statement on CMS National Coverage Determination for Drugs Used to Treat Patients Suffering from Alzheimer’s Disease
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why […]
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample
In recent years, researchers have begun to explore the vast assemblage of microbes on and within the human body. These include protists, archaea, fungi, viruses and vast numbers of bacteria living in symbiotic ecosystems.
TUCSON, AZ / ACCESSWIRE / April 4, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation has published another study touting the effectiveness of its anti-inflammatory ALT-100 monoclonal antibody (mAb)
- Digital RESI & Innovator Pitch Challenge June-- 50% Discount off Registration
- 06/07/2022 - 06/09/2022
- BIO International Convention
- 06/13/2022 - 06/16/2022
- San Diego
- AZBioPEERS: Tales from the Road - Tassos Gianakakos
- Venom Week VIII at SkySong
- 07/18/2022 - 07/21/2022
- AZBioPEERS: Business Basics Series- How To Build An Investable Team